Pregabalin Capsule
Product Images NDC 50090-6504

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-6504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906504)

Pregabalin 200 mg capsules label by A-S Medication Solutions showing the NDC 50090-6504-0. The label specifies one capsule contains 200 mg of pregabalin, storage instructions at 77 degrees F, and a package size of 60 capsules. Additional text includes lot and product numbers, dosing reference, and packaging location in Libertyville, IL.*

FDA Label Image

Equation (Pregabain Gault Equation)

A pharmacokinetic formula showing creatinine clearance (CLCr) calculation based on age, weight, and serum creatinine, with an adjustment factor for female patients. This panel is likely used to assess renal function relevant to drug dosing calculations.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline across different dosages of Pregabalin compared to placebo. The graph includes data for Pregabalin 200 mg, 100 mg, and 25 mg taken three times a day, with curves showing higher patient improvement at higher dosages relative to placebo.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve chart showing the percent of patients improved (Y-axis) versus percent improvement in pain from baseline (X-axis). It compares Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line), illustrating patient improvement over increasing thresholds of pain relief.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg two times a day, Pregabalin 150 mg two times a day, Pregabalin 75 mg two times a day, and placebo. The y-axis represents percent of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier style chart depicting the percent of patients improved versus percent improvement in pain from baseline. The chart compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows percent of patients improved (0 to 100%), and the x-axis shows percent improvement in pain from baseline (from >0 to 100%).*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph displaying percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and Placebo (dotted line). The chart shows higher percentages of patient improvement with Pregabalin doses compared to placebo.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar graph displaying responder rates (%) for different dosages of pregabalin and placebo in two clinical studies labeled Study E1 and Study E3. The x-axis shows dosages and administration frequencies, and the y-axis shows responder rates up to 60%. Study E1 includes placebo, 50 mg, 150 mg, 300 mg, and 600 mg doses given twice daily (BID). Study E3 includes placebo, and 600 mg doses given BID or three times daily (TID). Sample sizes (N) are shown below each group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. The graph includes four data series labeled Stukly E1BID, E2BID, E3BID, and E3TID, each represented by different symbols. P-values for significant changes are indicated next to data points. The x-axis represents dose (mg/day) and the y-axis represents seizure reduction.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, with four distinct line patterns representing each group. The y-axis represents percent of patients improved (0-100%), and the x-axis represents percent improvement in pain from baseline (0-100%).*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The x-axis represents the number of days, and the y-axis shows the estimated percentage of subjects without LTR, ranging from 0% to 100%. Two curves are shown: a solid line for Pregabalin and a dashed line for placebo, illustrating differences in subject outcomes over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percentage of subjects improved with Pregabalin versus Placebo over a range of percent improvement from baseline to week 12 (BOCF). The solid line represents Pregabalin showing a higher percent of subjects improved across the range compared to the dashed line for Placebo. The x-axis shows percent improved from baseline to week 12 and the y-axis shows percent of subjects improved up to 100%.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A cumulative distribution plot showing the percent of subjects improved on the vertical axis against the percent improved from baseline to Week 16 on the horizontal axis. Two lines compare Pregabalin to Placebo, with Pregabalin represented by a solid line and Placebo by a dashed line. The plot illustrates higher improvement percentages for subjects treated with Pregabalin compared to Placebo over time.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure diagram of pregabalin showing carbon, hydrogen, nitrogen, and oxygen atoms arranged to depict the active ingredient's molecular layout.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.